Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of ...

Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular ...

It’s now a standard part of diagnostic testing for some cancers, as it can provide very specific information. Keep reading to learn how IHC works and why it’s often an essential tool for doctors.

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize ... United States that has historically and is currently offering the [MET IHC] assay for ...

Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in ...

The global immunohistochemistry (IHC) market is experiencing steady growth, with a compound annual growth rate (CAGR) of ...

Foundation Medicine Expands Immunohistochemistry (IHC) Testing Portfolio to Include MET IHC Testing ...

Tempus will notify physicians of patients who are identified by the algorithm as more likely to be HER2 positive, so that they can consider ordering confirmatory IHC testing from their laboratory ...